{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:07:22Z","timestamp":1788872842749,"version":"build-2803163510"},"reference-count":93,"publisher":"Institute of Biochemistry","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BIOMED KHIM"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>Isatin (indol-2,3-dione) is an endogenous regulator found in humans and animals. It interacts with numerous target proteins and exhibits a wide range of biological activities, including neuroprotective action in animal models of Parkinson\u2019s disease (PD) induced by administration of neurotoxins MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) or rotenone. An antipsychotic drug haloperidol, which impairs neurotransmitter balance in the nigrostriatal pathway, models dopamine deficiency and promotes the development of motor disorders characteristic of PD. In this work, the effect of two doses of isatin (10 mg\/kg and 80 mg\/kg) on the haloperidol catalepsy and on the proteomic profile of mice brain was investigated. The pretreatment of animals with isatin (1 h before haloperidol administration) reduced the occurrence of haloperidol catalepsy. The administration of haloperidol and also isatin with haloperidol influenced the relative content of a number of proteins associated with PD and other neurodegenerative diseases.<\/jats:p>","DOI":"10.18097\/pbmcr1718","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:12:51Z","timestamp":1788869571000},"page":"267-278","source":"Crossref","is-referenced-by-count":0,"title":["The influence of neuroprotector isatin on haloperidolinduced catalepsy and proteomic profile of mice brain"],"prefix":"10.18097","volume":"72","author":[{"given":"O.A.","family":"Buneeva","sequence":"first","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.G.","family":"Kapitsa","sequence":"additional","affiliation":[{"name":"Zakusov Institute of Pharmacology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.G.","family":"Zavyalova","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Kaloshina","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.G.","family":"Zgoda","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.E.","family":"Medvedev","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7443","published-online":{"date-parts":[[2026]]},"reference":[{"key":"ref1","unstructured":"Medvedev A., Buneeva O., Glover V. (2007) Biological targets for isatin and its analogues: implications for therapy. Biologics, 1(2), 151\u2013162."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Medvedev A., Buneeva O., Gnedenko O., Ershov P., Ivanov A. (2018) Isatin, an endogenous nonpeptide biofactor: a review of its molecular targets, mechanisms of actions, and their biomedical implications. Biofactors, 44(2), 95\u2013108.","DOI":"10.1002\/biof.1408"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Buneeva O., Medvedev A. (2025) Monoamine oxidase inhibitors in toxic models of parkinsonism. Int. J. Mol. Sci., 26(3), 1248.","DOI":"10.3390\/ijms26031248"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Buneeva O.A., Kapitsa I.G., Kazieva L.Sh., Vavilov N.E., Zgoda V.G., Medvedev A.E. (2024) The delayed effect of rotenone on the relative content of brain isatin-binding proteins of rats with experimental parkinsonism. Biomeditsinskaya Khimiia, 70(1), 25\u201332.","DOI":"10.18097\/PBMC20247001025"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Buneeva O., Kopylov A., Kapitsa I., Ivanova E., Zgoda V., Medvedev A. (2018) The effect of neurotoxin MPTP and neuroprotector isatin on the profile of ubiquitinated brain mitochondrial proteins. Cells, 7(8), 91.","DOI":"10.3390\/cells7080091"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Kapitsa I.G., Buneeva O.A., Kazieva L.Sh., Vavilov N.E., Zgoda V.G., Kopylov A.T., Medvedev A.E. (2023) Characteristics of behavioral reactions and the profile of brain isatin-binding proteins of rats with the rotenone-induced experimental parkinsonism. Biomeditsinskaya Khimiya, 69(1), 46\u201354.","DOI":"10.18097\/PBMC20236901046"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Singer T.P., Ramsay R.R. (1990) Mechanism of the neurotoxicity of MPTP: an update. FEBS Lett., 274(1\u20132), 1\u20138.","DOI":"10.1016\/0014-5793(90)81315-F"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Buneeva O.A., Kapitsa I.G., Kazieva L.Sh., Vavilov N.E., Zgoda V.G., Medvedev A.E. (2024) The neuroprotective effect of isatin in the rotenone-induced model of parkinsonism in rats: the study of delayed effects. Biomeditsinskaya Khimiya, 70(4), 231\u2013239.","DOI":"10.18097\/pbmc20247004231"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Buneeva O.A., Kapitsa I.G., Kazieva L.Sh., Vavilov N.E., Zgoda V.G. (2023) Quantitative changes of brain isatin-binding proteins of rats with the rotenone-induced experimental parkinsonism. Biomeditsinskaya Khimiya, 69(3), 188\u2013192.","DOI":"10.18097\/PBMC20236903188"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Waku I., Magalh\u00e3es M.S., Alves C.O., de Oliveira A.R. (2021) Haloperidol-induced catalepsy as an animal model for parkinsonism: a systematic review of experimental studies. Eur. J. Neurosci., 53(11), 3743\u20133767.","DOI":"10.1111\/ejn.15222"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Sharma A.K., Gupta S., Patel R.K., Wardhan N. (2018) Haloperidol-induced parkinsonism is attenuated by varenicline in mice. J. Basic Clin. Physiol. Pharmacol., 29(4), 395\u2013401.","DOI":"10.1515\/jbcpp-2017-0107"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Kabra A., Baghel U.S., Hano C., Martins N., Khalid M., Sharma R. (2020) Neuroprotective potential of Myrica esculenta in haloperidol induced Parkinson\u2019s disease. J. Ayurveda Integr. Med., 11(4), 448\u2013454.","DOI":"10.1016\/j.jaim.2020.06.007"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Valdman E., Kapitsa I., Ivanova \u0415., Voronina T., Ardashov O., Volcho K., Khazanov V., Salakhutdinov N. (2017) Evolution of anti-parkinsonian activity of monoterpenoid (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene- 1,2-diol in various in vivo models. Eur. J. Pharmacol., 815, 351\u2013363.","DOI":"10.1016\/j.ejphar.2017.09.022"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Hattori K., Uchino S., Isosaka T., Maekawa M., Iyo M., Sato T., Kohsaka S., Yagi T., Yuasa S. (2006) Fyn is required for haloperidol-induced catalepsy in mice. J. Biol. Chem., 281(11), 7129\u20137135.","DOI":"10.1074\/jbc.M511608200"},{"key":"ref15","unstructured":"Ivanova E.A., Nepoklonov A.V., Kokshenev I.I., Kapitsa I.G., Voronina T.A., Valdman E.A. (2012) Study of anticataleptic activity of hemantane using different routes of drug administration and in combination with levodopa. Biomedicine, 1, 74\u201381."},{"key":"ref16","unstructured":"Voronina T.A., Valdman E.A., Nerobkova L.N., Kapitsa I.G. (2012) Guidelines for preclinical studies of drugs with antiparkinsonian activity. In: Guidelines for Conducting Preclinical Studies of Drugs. Part One (Mironov A.N., ed.), Moscow: Grif i K, pp. 251\u2013263."},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Volpe J.J. (2008) Hyperammonemia and other disorders of amino acid metabolism. In: Neurology of the Newborn (Fifth Edition) (Volpe J.J., ed.). W.B. Saunders, Philadelphia, pp. 652\u2013685.","DOI":"10.1016\/B978-1-4160-3995-2.10014-7"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Zhang L., Zou Y., Lu Y., Li Z., Gao F. (2023) Unraveling the therapeutic potential of carbamoyl phosphate synthetase 1 (CPS1) in human diseases. Bioorg. Chem., 130, 106253.","DOI":"10.1016\/j.bioorg.2022.106253"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"H\u00e4berle J., Shchelochkov O.A., Wang J., Katsonis P., Hall L., Reiss S., Eeds A., Willis A., Yadav M., Summar S.; Urea Cycle Disorders Consortium; Lichtarge O., Rubio V., Wong L.-J., Summar M. (2011) Molecular defects in human carbamoyl phosphate synthetase I: mutational spectrum, diagnostic and protein structure considerations. Hum. Mutat., 32(6), 579\u2013589.","DOI":"10.1002\/humu.21406"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Chen B., Zhang Q., Zhong X., Zhang X., Liu X., Wang H., Yang F., Zhang J., Huang J., Wong Y.-K., Luo P., Wang J., Sun J. (2024) Dopamine modification of glycolytic enzymes impairs glycolysis: possible implications for Parkinson\u2019s disease. Cell Commun. Signal., 22, 75.","DOI":"10.1186\/s12964-024-01478-0"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Luo J.J., Zhang L., Dun N.J. (2022) Homocysteine and dementia in Parkinson disease. In: Dementia in Parkinson\u2019s Disease \u2014 Everything You Need to Know. IntechOpen, 238 p.","DOI":"10.5772\/intechopen.100192"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Martignoni E., Tassorelli C., Nappi G., Zangaglia R., Pacchetti C., Blandini F. (2007) Homocysteine and Parkinson\u2019s disease: a dangerous liaison? J. Neurol. Sci., 257(1\u20132), 31\u201337.","DOI":"10.1016\/j.jns.2007.01.028"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Zhou L. (2024) Homocysteine and Parkinson\u2019s disease. CNS Neurosci. Ther., 30(2), e14420.","DOI":"10.1111\/cns.14420"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Naoi M., Maruyama W., Inaba-Hasegawa K. (2012) Type A and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival. Curr. Top. Med. Chem., 12(20), 2177\u20132188.","DOI":"10.2174\/156802612805219950"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Alborghetti M., Bianchini E., de Carolis L., Galli S., Pontieri F.E., Rinaldi D. (2024) Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings. Neural Regen. Res., 19(1), 16\u201321.","DOI":"10.4103\/1673-5374.375299"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Arnold S. (2012) Cytochrome c oxidase and its role in neurodegeneration and neuroprotection. Adv. Exp. Med. Biol., 748, 305\u2013339.","DOI":"10.1007\/978-1-4614-3573-0_13"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Erhardt B., Marcora M.S., Frenkel L., Bochicchio P.A., Bodin D.H., Silva B.A., Far\u00edas M.I., Allo M.\u00c1., H\u00f6cht C., Ferrari C.C., Pitossi F.J., Leal M.C. (2021) Plasma membrane calcium ATPase downregulation in dopaminergic neurons alters cellular physiology and motor behaviour in Drosophila melanogaster. Eur. J. Neurosci., 54(6), 5915\u20135931.","DOI":"10.1111\/ejn.15401"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Ebanks B., Chakrabarti L. (2022) Mitochondrial ATP synthase is a target of oxidative stress in neurodegenerative diseases. Front. Mol. Biosci., 9, 854321.","DOI":"10.3389\/fmolb.2022.854321"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Anvret A., Ran C., Westerlund M., Sydow O., Willows T., Olson L., Galter D., Belin A.C. (2012) Genetic screening of the mitochondrial Rho GTPases MIRO1 and MIRO2 in Parkinson\u2019s disease. Open Neurol. J., 6, 1\u20135.","DOI":"10.2174\/1874205X01206010001"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Alberio T., McMahon K., Cuccurullo M., Gethings L.A., Lawless C., Zibetti M., Lopiano L., Vissers J.P.C., Fasano M. (2014) Verification of a Parkinson\u2019s disease protein signature in T-lymphocytes by multiple reaction monitoring. J. Proteome Res., 13(8), 3554\u20133561.","DOI":"10.1021\/pr401142p"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Santulli C., Bon C., de Cecco E., Codrich M., Narkiewicz J., Parisse P., Perissinotto F., Santoro C., Persichetti F., Legname G., Espinoza S., Gustincich S. (2022) Neuronal haemoglobin induces loss of dopaminergic neurons in mouse substantia nigra, cognitive deficits and cleavage of endogenous \u03b1-synuclein. Cell Death Dis., 13(12), 1048.","DOI":"10.1038\/s41419-022-05489-y"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Graham J., Hobson D., Ponnampalam A. (2014) High affinity hemoglobin and Parkinson\u2019s disease. Med. Hypotheses, 83(6), 819\u2013821.","DOI":"10.1016\/j.mehy.2014.10.016"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Padhan P., Simran, Kumar N., Verma S. (2025) Glutathione S-transferase: a keystone in Parkinson\u2019s disease pathogenesis and therapy. Mol. Cell. Neurosci., 132, 103981.","DOI":"10.1016\/j.mcn.2024.103981"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Kim J.H., Lee H.-K., Takamiya K., Huganir R.L. (2003) The role of synaptic GTPase-activating protein in neuronal development and synaptic plasticity. J. Neurosci., 23(4), 1119\u20131124.","DOI":"10.1523\/JNEUROSCI.23-04-01119.2003"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Masoudi N., Ibanez-Cruceyra P., Offenburger S.-L., Holmes A., GartnerA. (2014) Tetraspanin (TSP-17) protects dopaminergic neurons against 6-OHDA-induced neurodegeneration in C. elegans. PLOS Genet., 10(12), e1004767.","DOI":"10.1371\/journal.pgen.1004767"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Warth Perez Arias C.C., Silbern I., Caldi Gomes L., Wartmann H., Dambeck V., Fanz J., Neuenroth L., B\u00e4hr M., Outeiro T.F., Bonn S., Stadelmann-Nessler C., Rizzoli S.O., Lenz C., Urlaub H., Lingor P. (2023) Proteomic analysis of the human hippocampus identifies neuronal pentraxin 1 (NPTX1) as synapto-axonal target in late-stage Parkinson\u2019s disease. J. Neurochem., 166(5), 862\u2013874.","DOI":"10.1111\/jnc.15924"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"G\u00f3mez de San Jos\u00e9 N., Massa F., Halbgebauer S., Oeckl P., Steinacker P., Otto M. (2022) Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration. J. Neural Transm., 129(2), 207\u2013230.","DOI":"10.1007\/s00702-021-02411-2"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Wang C., Kang X., Zhou L., Chai Z., Wu Q., Huang R., Xu H., Hu M., Sun X., Sun S., Li J., Jiao R., Zuo P., Zheng L., Yue Z., Zhou Z. (2018) Synaptotagmin-11 is a critical mediator of parkin-linked neurotoxicity and Parkinson\u2019s disease-like pathology. Nat. Commun., 9, 81.","DOI":"10.1038\/s41467-017-02593-y"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Ho G.P.H., Wilkie E.C., White A.J., Selkoe D.J. (2023) Palmitoylation of the Parkinson\u2019s disease-associated protein synaptotagmin-11 links its turnover to \u03b1-synuclein homeostasis. Sci. Signal., 16(772), eadd7220.","DOI":"10.1126\/scisignal.add7220"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Mazzetti S., Giampietro F., Calogero A.M., Isilgan H.B., Gagliardi G., Rolando C., Cantele F., Ascagni M., Bramerio M., Giaccone G., Isaias I.U., Pezzoli G., Cappelletti G. (2024) Linking acetylated \u03b1-tubulin redistribution to \u03b1-synuclein pathology in brain of Parkinson\u2019s disease patients. NPJ Parkinsons Dis., 10, 2.","DOI":"10.1038\/s41531-023-00607-9"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Ren Y., Zhao J., Feng J. (2003) Parkin binds to \u03b1\/\u03b2 tubulin and increases their ubiquitination and degradation. J. Neurosci., 23(8), 3316\u20133324.","DOI":"10.1523\/JNEUROSCI.23-08-03316.2003"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Shi X., Jiang X., Chen C., Zhang Y., Sun X. (2022) The interconnections between the microtubules and mitochondrial networks in cardiocerebrovascular diseases: implications for therapy. Pharmacol. Res., 184, 106452.","DOI":"10.1016\/j.phrs.2022.106452"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Zhou X., Liao W.-J., Liao J.-M., Liao P., Lu H. (2015) Ribosomal proteins: functions beyond the ribosome. J. Mol. Cell Biol., 7(2), 92\u2013104.","DOI":"10.1093\/jmcb\/mjv014"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Wang W., Nag S., Zhang X., Wang M.-H., Wang H., Zhou J., Zhang R. (2015) Ribosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implications. Med. Res. Rev., 35(2), 225\u2013285.","DOI":"10.1002\/med.21327"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Egorova P.A., Bezprozvanny I.B. (2018) Inositol 1,4,5-trisphosphate receptors and neurodegenerative disorders. FEBS J., 285(19), 3547\u20133565.","DOI":"10.1111\/febs.14366"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Duan W., Ladenheim B., Cutler R.G., Kruman I.I., Cadet J.L., Mattson M.P. (2002) Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson\u2019s disease. J. Neurochem., 80(1), 101\u2013110.","DOI":"10.1046\/j.0022-3042.2001.00676.x"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Bhatt M., di Iacovo A., Romanazzi T., Roseti C., Bossi E. (2023) Betaine \u2014 the dark knight of the brain. Basic Clin. Pharmacol. Toxicol., 133(5), 485\u2013495.","DOI":"10.1111\/bcpt.13839"},{"key":"ref48","unstructured":"Chen C.-H., Joshi A.U., Mochly-Rosen D. (2016) The role of mitochondrial aldehyde dehydrogenase 2 (ALDH2) in neuropathology and neurodegeneration. Acta Neurol. Taiwan., 25(4), 111\u2013123."},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Lee T.V., Chen C., Allison K.S., Li Y., Al-Ramahi I., Bagchi P., Levey A.I., Botas J., Seyfried N.T., Shulman J.M. (2023) The cytoskeletal protein plectin regulates Tau-induced neurotoxicity in Alzheimer\u2019s disease. Alzheimers Dement., 19(S12), e078952.","DOI":"10.1002\/alz.078952"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"McMillan H.J., Worthylake T., Schwartzentruber J., Gottlieb C.C., Lawrence S.E., Mackenzie A., Beaulieu C.L., Mooyer P.A.W.; FORGE Canada Consortium; Wanders R.J.A., Majewski J., Bulman D.E., Geraghty M.T., Ferdinandusse S., Boycott K.M. (2012) Specific combination of compound heterozygous mutations in 17\u03b2-hydroxysteroid dehydrogenase type 4 (HSD17B4) defines a new subtype of D-bifunctional protein deficiency. Orphanet J. Rare Dis., 7, 90.","DOI":"10.1186\/1750-1172-7-90"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Li X., Yu L., Liu X., Shi T., Zhang Y., Xiao Y., Wang C., Song L., Li N., Liu X., Chen Y., Petersen R.B., Cheng X., Xue W., Yu Y.V., Xu L., Zheng L., Chen H., Huang K. (2024) \u03b2-Synuclein regulates the phase transitions and amyloid conversion of \u03b1-synuclein. Nat. Commun., 15, 8748.","DOI":"10.1038\/s41467-024-53086-8"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Barba L., Paolini Paoletti F., Bellomo G., Gaetani L., Halbgebauer S., Oeckl P., Otto M., Parnetti L. (2022) Alpha and beta synucleins: from pathophysiology to clinical application as biomarkers. Mov. Disord., 37(4), 669\u2013683.","DOI":"10.1002\/mds.28941"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Chung I., Park H.-A, Kang J., Kim H., Hah S.M., Lee J., Kim H.S., Choi W.-S., Chung J.H., Shin M.-J. (2022) Neuroprotective effects of ATPase inhibitory factor 1 preventing mitochondrial dysfunction in Parkinson\u2019s disease. Sci. Rep., 12, 3874.","DOI":"10.1038\/s41598-022-07851-8"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Severa M., Zhang J., Giacomini E., Rizzo F., Etna M.P., Cruciani M., Garaci E., Chopp M., Coccia E.M. (2019) Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application. Mult. Scler. Relat. Disord., 27, 52\u201360.","DOI":"10.1016\/j.msard.2018.09.035"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Xing Y., Ye Y., Zuo H., Li Y. (2021) Progress on the function and application of thymosin \u03b24. Front. Endocrinol., 12, 767785.","DOI":"10.3389\/fendo.2021.767785"},{"key":"ref56","unstructured":"Towns T.J. (2024) An investigation into the varied roles of phosphoprotein enriched in astrocytes-15kD (PEA15) in energy metabolism, metabolic flexibility, and gyrencephalic neurodevelopment. PhD Dissertation, Auburn University, Auburn, AL."},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Ma X., Zhang H., Yin H., Geng S., Liu Y., Liu C., Zhao J., Liu Y., Wang X., Wang Y. (2021) Up-regulated microRNA-218-5p ameliorates the damage of dopaminergic neurons in rats with Parkinson\u2019s disease via suppression of LASP1. Brain Res. Bull., 166, 92\u2013101.","DOI":"10.1016\/j.brainresbull.2020.10.019"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Phillips G.R., Anderson T.R., Florens L., Gudas C., Magda G., Yates J.R. 3rd, Colman D.R. (2004) Actin-binding proteins in a postsynaptic preparation: lasp-1 is a component of central nervous system synapses and dendritic spines. J. Neurosci. Res., 78, 38\u201348.","DOI":"10.1002\/jnr.20224"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Walensky L.D., Shi Z.T., Blackshaw S., DeVries A.C., Demas G.E., Gascard P., Nelson R.J., Conboy J.G., Rubin E.M., Snyder S.H., Mohandas N. (1998) Neurobehavioral deficits in mice lacking the erythrocyte membrane cytoskeletal protein 4.1. Curr. Biol., 8(23), 1269\u20131272.","DOI":"10.1016\/s0960-9822(07)00536-2"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Hagmeyer S., Rom\u00e3o M.A., Crist\u00f3v\u00e3o J.S., Vilella A., Zoli M., Gomes C.M., Grabrucker A.M. (2019) Distribution and relative abundance of S100 proteins in the brain of the APP23 Alzheimer\u2019s disease model mice. Front. Neurosci., 13, 640.","DOI":"10.3389\/fnins.2019.00640"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Crist\u00f3v\u00e3o J.S., Gomes C.M. (2019) S100 proteins in Alzheimer\u2019s disease. Front. Neurosci., 13, 463.","DOI":"10.3389\/fnins.2019.00463"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Bar-Am O., Yogev-Falach M., Amit T., Sagi Y., Youdim M.B.H. (2004) Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J. Neurochem., 89(5), 1119\u20131125.","DOI":"10.1111\/j.1471-4159.2004.02425.x"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Chen Z., Zhang W., Selmi C., Ridgway W.M., Leung P.S.C., Zhang F., Gershwin M.E. (2021) The myristoylated alanine-rich C-kinase substrates (MARCKS): a membraneanchored mediator of the cell function. Autoimmun. Rev., 20(11), 102942.","DOI":"10.1016\/j.autrev.2021.102942"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Gagliardi D., Pagliari E., Meneri M., Melzi V., Rizzo F., Comi G.P., Corti S., Taiana M., Nizzardo M. (2022) Stathmins and motor neuron diseases: pathophysiology and therapeutic targets. Biomedicines, 10(3), 711.","DOI":"10.3390\/biomedicines10030711"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Nelke A., Garc\u00eda-L\u00f3pez S., Mart\u00ednez-Serrano A., Pereira M.P. (2022) Multifactoriality of Parkinson\u2019s disease as explored through human neural stem cells and their transplantation in middle-aged Parkinsonian mice. Front. Pharmacol., 12, 773925.","DOI":"10.3389\/fphar.2021.773925"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Dagda R.K., Banerjee T.D. (2015) Role of PKA in regulating mitochondrial function and neuronal development: implications to neurodegenerative diseases. Rev. Neurosci., 26(3), 359\u2013370.","DOI":"10.1515\/revneuro-2014-0085"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Greggio E., Bubacco L., Russo I. (2017) Cross-talk between LRRK2 and PKA: implication for Parkinson\u2019s disease? Biochem. Soc. Trans., 45(1), 261\u2013267.","DOI":"10.1042\/BST20160396"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Flerlage W.J., dell\u2019Acqua M.L., Cox B.M., Nugent F.S. (2025) Emerging role of A-kinase anchoring protein 5 signaling in reward circuit function. Neural Regen. Res., 20(10), 2913\u20132914.","DOI":"10.4103\/NRR.NRR-D-24-00759"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Remnest\u00e5l J., Just D., Mitsios N., Fredolini C., Mulder J., Schwenk J.M., Uhl\u00e9nM., Kultima K., IngelssonM., Kilander L., Lannfelt L., Svenningsson P., Nellg\u00e5rd B., Zetterberg H., Blennow K., Nilsson P., H\u00e4ggmark-M\u00e5nberg A. (2016) CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer\u2019s disease. Proteomics Clin. Appl., 10(12), 1242\u20131253.","DOI":"10.1002\/prca.201500150"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Calabresi P., Mechelli A., Natale G., Volpicelli-Daley L., di Lazzaro G., Ghiglieri V. (2023) Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis., 14(3), 176.","DOI":"10.1038\/s41419-023-05672-9"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Stefanis L. (2012) \u03b1-Synuclein in Parkinson\u2019s disease. Cold Spring Harb. Perspect. Med., 2(2), a009399.","DOI":"10.1101\/cshperspect.a009399"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Santaella A., Kuiperij H.B., van Rumund A., Esselink R.A.J., Bloem B.R., Verbeek M.M. (2020) Cerebrospinal fluid myelin basic protein is elevated in multiple system atrophy. Parkinsonism Relat. Disord., 76, 80\u201384.","DOI":"10.1016\/j.parkreldis.2020.06.004"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Alieva A.K., Zyrin V.S., Rudenok M.M., Kolacheva A.A., Shulskaya M.V., Ugryumov M.V., Slominsky P.A., Shadrina M.I. (2018) Whole-transcriptome analysis of mouse models with MPTP-induced early stages of Parkinson\u2019s disease reveals stage-specific response of transcriptome and a possible role of myelin-linked genes in neurodegeneration. Mol. Neurobiol., 55(9), 7229\u20137241.","DOI":"10.1007\/s12035-018-0907-1"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Huang Z.-N., Chung H.M., Fang S.-C., Her L.-S. (2017) Adhesion regulating molecule 1 mediates HAP40 overexpression-induced mitochondrial defects. Int. J. Biol. Sci., 13(11), 1420\u20131437.","DOI":"10.7150\/ijbs.20742"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Siddique I., Kamble K., Gupta S., Solanki K., Bhola S., Ahsan N., Gupta S. (2023) ARL6IP5 ameliorates \u03b1-synuclein burden by inducing autophagy via preventing ubiquitination and degradation of ATG12. Int. J. Mol. Sci., 24(13), 10499.","DOI":"10.3390\/ijms241310499"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Zhang X., Zhou J.-Y., Chin M.H., Schepmoes A.A., Petyuk V.A., Weitz K.K., Petritis B.O., Monroe M.E., Camp D.G.,Wood S.A., Melega W.P., Bigelow D.J., Smith D.J., Qian W.-J., Smith R.D. (2010) Region-specific protein abundance changes in the brain of MPTP-induced Parkinson\u2019s disease mouse model. J. Proteome Res., 9(3), 1496\u20131509.","DOI":"10.1021\/pr901024z"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Pellegrini L., Wetzel A., Grann\u00f3 S., Heaton G., Harvey K. (2016) Back to the tubule: microtubule dynamics in Parkinson\u2019s disease. Cell. Mol. Life Sci., 74(3), 409\u2013434.","DOI":"10.1007\/s00018-016-2351-6"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Calogero A.M., Mazzetti S., Pezzoli G., Cappelletti G. (2019) Neuronal microtubules and proteins linked to Parkinson\u2019s disease: a relevant interaction? Biol. Chem., 400(9), 1099\u20131112.","DOI":"10.1515\/hsz-2019-0142"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Naren P., Samim K.S., Tryphena K.P., Vora L.K., Srivastava S., Singh S.B., Khatri D.K. (2023) Microtubule acetylation dyshomeostasis in Parkinson\u2019s disease. Transl. Neurodegener., 12, 20.","DOI":"10.1186\/s40035-023-00354-0"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Ma L., Song J., Sun X., Ding W., Fan K., Qi M., Xu Y., Zhang W. (2019) Role of microtubule-associated protein 6 glycosylated with Gal-(\u03b2-1,3)-GalNAc in Parkinson\u2019s disease. Aging (Albany NY), 11(13), 4597\u20134610.","DOI":"10.18632\/aging.102072"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Brotchie J.M. (2003) CB1 cannabinoid receptor signalling in Parkinson\u2019s disease. Curr. Opin. Pharmacol., 3(1), 54\u201361.","DOI":"10.1016\/S1471-4892(02)00011-5"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Arrazola Sastre A., Luque Montoro M., G\u00e1lvez-Mart\u00edn P., Lacerda H.M., Lucia A.M., Llavero F., Zugaza J.L. (2020) Small GTPases of the Ras and Rho families switch on\/off signaling pathways in neurodegenerative diseases. Int. J. Mol. Sci., 21(17), 6312.","DOI":"10.3390\/ijms21176312"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Berger I., Hershkovitz E., Shaag A., Edvardson S., Saada A., Elpeleg O. (2008) Mitochondrial complex I deficiency caused by a deleterious NDUFA11 mutation. Ann. Neurol., 63(3), 405\u2013408.","DOI":"10.1002\/ana.21332"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Becic A., Leifeld J., Shaukat J., Hollmann M. (2022) Tetraspanins as potential modulators of glutamatergic synaptic function. Front. Mol. Neurosci., 14, 801882.","DOI":"10.3389\/fnmol.2021.801882"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Lau A., Tymianski M. (2010) Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch., 460(2), 525\u2013542.","DOI":"10.1007\/s00424-010-0809-1"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Greig F.H., Nixon G.F. (2014) Phosphoprotein enriched in astrocytes (PEA)-15: a potential therapeutic target in multiple disease states. Pharmacol. Ther., 143(3), 265\u2013274.","DOI":"10.1016\/j.pharmthera.2014.03.006"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Peng X., Wellard N., Ghosh A., Troakes C., Giese K.P. (2024) Different dysregulations of CYFIP1 and CYFIP2 in distinct types of dementia. Brain Res. Bull., 206, 110849.","DOI":"10.1016\/j.brainresbull.2023.110849"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Liang Z., Liu F., Grundke-Iqbal I., Iqbal K., Gong C.-X. (2007) Down-regulation of cAMP-dependent protein kinase by over-activated calpain in Alzheimer disease brain. J. Neurochem., 103(6), 2462\u20132470.","DOI":"10.1111\/j.1471-4159.2007.04942.x"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Wu X., Yang Z., Zou J., Gao H., Shao Z., Li C., Lei P. (2025) Protein kinases in neurodegenerative diseases: current understandings and implications for drug discovery. Signal Transduct. Target. Ther., 10, 146.","DOI":"10.1038\/s41392-025-02179-x"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Yang Y., Qin M., Bao P., Xu W., Xu J. (2017) Secretory carrier membrane protein 5 is an autophagy inhibitor that promotes the secretion of \u03b1-synuclein via exosome. PLOS One, 12(7), e0180892.","DOI":"10.1371\/journal.pone.0180892"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Buneeva O.A., Kapitsa I.G., Zgoda V.G., Medvedev A.E. (2023) Neuroprotective effects of isatin and afobazole in rats with rotenone-induced parkinsonism are accompanied by increased brain levels of Triton X-100 soluble alpha-synuclein. Biomeditsinskaya Khimiya, 69(5), 290\u2013299.","DOI":"10.18097\/PBMC20236905290"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Susa K.J., Kruse A.C., Blacklow S.C. (2024) Tetraspanins: structure, dynamics, and principles of partner-protein recognition. Trends Cell Biol., 34(6), 509\u2013522.","DOI":"10.1016\/j.tcb.2023.09.003"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Guix F.X., Sannerud R., Berditchevski F., Arranz A.M., Horr\u00e9 K., Snellinx A., Thathiah A., Saido T., Saito T., Rajesh S., Overduin M., Kumar-Singh S., Radaelli E., Corthout N., Colombelli J., Tosi S., Munck S., Salas I.H., Annaert W., de Strooper B. (2017) Tetraspanin 6: a pivotal protein of the multiple vesicular body determining exosome release and lysosomal degradation of amyloid precursor protein fragments. Mol. Neurodegener., 12, 25.","DOI":"10.1186\/s13024-017-0165-0"}],"container-title":["Biomeditsinskaya Khimiya"],"original-title":[],"language":"ru","deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:13:02Z","timestamp":1788869582000},"score":1,"resource":{"primary":{"URL":"http:\/\/pbmc.ibmc.msk.ru\/en\/article-en\/PBMC-2026-72-4-267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":93,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026]]},"published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.18097\/pbmcr1718","relation":{},"ISSN":["2310-6905","2310-6972"],"issn-type":[{"value":"2310-6905","type":"electronic"},{"value":"2310-6972","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}